Chimerix (NASDAQ:CMRX - Get Free Report) released its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.01, Zacks reports. The company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million.
Chimerix Price Performance
Shares of NASDAQ:CMRX traded up $0.01 during midday trading on Monday, reaching $8.51. The company's stock had a trading volume of 653,326 shares, compared to its average volume of 2,096,914. The business's fifty day simple moving average is $5.34 and its 200-day simple moving average is $2.85. The company has a market capitalization of $764.91 million, a P/E ratio of -9.05 and a beta of 0.32. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $8.52.
Insider Transactions at Chimerix
In related news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 20,760 shares of company stock worth $91,175. Corporate insiders own 13.10% of the company's stock.
Analyst Ratings Changes
Several analysts recently commented on CMRX shares. HC Wainwright reaffirmed a "neutral" rating and issued a $8.55 price target (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush restated a "neutral" rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com initiated coverage on shares of Chimerix in a research report on Sunday. They set a "hold" rating for the company. Finally, Jefferies Financial Group restated a "hold" rating and issued a $8.50 price target (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.
Read Our Latest Analysis on CMRX
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Featured Stories
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
